These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2568824)

  • 21. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
    Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbamazepine maintenance treatment in outpatient schizophrenics.
    Carpenter WT; Kurz R; Kirkpatrick B; Hanlon TE; Summerfelt AT; Buchanan RW; Waltrip RW; Breier A
    Arch Gen Psychiatry; 1991 Jan; 48(1):69-72. PubMed ID: 1670617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Course of treatment response in first-episode and chronic schizophrenia.
    Szymanski SR; Cannon TD; Gallacher F; Erwin RJ; Gur RE
    Am J Psychiatry; 1996 Apr; 153(4):519-25. PubMed ID: 8599400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    Shaw P; Sporn A; Gogtay N; Overman GP; Greenstein D; Gochman P; Tossell JW; Lenane M; Rapoport JL
    Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
    Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
    Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of the positive-negative distinction in schizophrenia.
    Kay SR
    Schizophr Bull; 1990; 16(4):635-52. PubMed ID: 2077641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone: how good is the evidence for efficacy?
    Mattes JA
    Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
    Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT
    Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
    Steingard S; Allen M; Schooler NR
    J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
    Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time course of antipsychotic effects of neuroleptic drugs.
    Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
    Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
    Paillère-Martinot ML; Lecrubier Y; Martinot JL; Aubin F
    Am J Psychiatry; 1995 Jan; 152(1):130-4. PubMed ID: 7802104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics.
    Beckmann H; Fritze J; Franzek E
    Neuropsychobiology; 1992; 26(1-2):50-8. PubMed ID: 1361971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.